{
  "id": "5c7c538f38e74840",
  "title": "Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ\u2122 for Leptomeningeal Metastases",
  "description": "20260108T204500Z",
  "content": "",
  "source": "portal.sina.com.hk",
  "source_url": "https://portal.sina.com.hk/finance/finance-globenewswire/globenewswire/2026/01/08/1432224/plus-therapeutics-announces-read-out-of-type-b-meeting-with-the-fda-with-goal-of-accelerating-approval-of-reyobiq-for-leptomeningeal-metastases/",
  "published_at": "20260108T204500Z",
  "fetched_at": "2026-01-09T00:23:18.491015+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "fda"
  ],
  "location": "Hong Kong",
  "raw_data": {
    "url": "https://portal.sina.com.hk/finance/finance-globenewswire/globenewswire/2026/01/08/1432224/plus-therapeutics-announces-read-out-of-type-b-meeting-with-the-fda-with-goal-of-accelerating-approval-of-reyobiq-for-leptomeningeal-metastases/",
    "url_mobile": "",
    "title": "Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ\u2122 for Leptomeningeal Metastases",
    "seendate": "20260108T204500Z",
    "socialimage": "https://ml.globenewswire.com/media/YmNhZTQwZjktNTMzNy00OGE1LTg4ZTEtYTg2OWFmYWY4YzM5LTEwMTYzNzgtMjAyNi0wMS0wOC1lbg==/tiny/Plus-Therapeutics-Inc-.png",
    "domain": "portal.sina.com.hk",
    "language": "English",
    "sourcecountry": "Hong Kong"
  }
}